Publication | Closed Access
Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
83
Citations
0
References
2012
Year
Breast OncologyCancer ManagementPathologyTumor BiologyOncologyMetronomic TherapyClinical OncologyRadiation OncologyCancer ResearchMolecular OncologyFinal TextMetastatic Breast CancerAsco Daily NewsCancer TreatmentMalignant DiseaseTrastuzumab EmtansineTumoral PathologyBreast CancerMedicinePhase Iii Study
LBA1 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.